TABLE 2.

Clinical assessment trajectories in anosmia and non-anosmia groups over visits: GEE analysis.

	Anosmia				Non-anosmia
	Visit 2 vs. visit 1		Visit 3 vs. visit 1		Visit 2 vs. visit 1		Visit 3 vs. visit 1
	Crude		Crude		Crude		Crude
	B	P	B	p	B	p	B	p
LEDD	204	<0.001*	253	0.004*	141	<0.001*	352	0.003*
UPSIT	−1.1	0.165	−0.1	0.893	−1.2	0.267	−2.3	0.005*
MoCA	−2.8	0.005*	−3.0	0.052	−0.7	0.274	0.2	0.831
M-UPDRS
Total	−2.1	0.700	1.8	0.653	−0.1	0.960	4.0	0.430
Part III	−1.2	0.638	2.9	0.261	2.0	0.258	3.2	0.283
PDQ-39
SI	−4.7	0.095	3.6	0.257	−1.5	0.673	−0.4	0.883
ADL	−6.0	0.157	1.8	0.594	−3.3	0.340	−4.1	0.274
COG	−5.4	0.186	2.1	0.725	−6.0	0.304	5.8	0.306

Results indicate a decrease in the UPSIT scores from baseline in the non-anosmia group (B = −2.3, p = 0.005) and a decline in the MoCA scores from baseline in the anosmia group (B = −2.8, p = 0.005). Anosmia: baseline UPSIT < 19; Non-anosmia: baseline UPSIT ≥ 19. Table 1 and the above table are related to Figure 1. ADL, activities of daily living; B, beta coefficient; COG, cognitions; GEE, generalized estimating equation; LEDD, levodopa equivalent daily dose; MoCA, Montreal cognitive assessment; M-UPDRS, Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale; PDQ-39, Chinese-translated version of 39-item Parkinson’s Disease Questionnaire; SI, summary index; UPSIT, traditional Chinese version of the University of Pennsylvania Smell Identification Test.

*p < 0.05.